Just last week, OptiScan Biomedical announced that its OptiScanner 5000 glucose monitoring system won 510(k) clearance for use in surgical intensive care units.
The regulatory win was supported by eight rigorous clinical trials, CEO Peter Rule told Drug Delivery Business News, and represents a victory for a technology that the company hopes to expand into a platform system.
Get the full story at our sister site, Drug Delivery Business News.
The post OptiScan CEO: Glucose monitor approval is biggest advancement for ICU care in 10 years appeared first on MassDevice.
from MassDevice http://ift.tt/2yKmGxm
Cap comentari:
Publica un comentari a l'entrada